Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 4/20 | 0.34 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.34 |
| ▸ | PEPD | P12955 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12892156 | 1.00 | GABRR1 (0.34) | GABRR1GABRR2PEPDBTKEPHX1 | |
| SCHEMBL24923284 | 0.82 | EPHX1 (0.36) | BTKEPHX1HRH3MAPK1HPGD | |
| SCHEMBL22447718 | 0.81 | CHRM2 (0.42) | GABRR1GABRR2PEPDCHRM2CHRM3 | |
| SCHEMBL1296115 | 0.78 | EPHX1 (0.41) | BTKEPHX1HRH3MAPK1HPGD | |
| SCHEMBL8788545 | 0.78 | PDE4B (0.34) | EPHX1HRH3GAA | |
| SCHEMBL8905563 | 0.78 | EPHX1 (0.33) | EPHX1HRH3GAA | |
| SCHEMBL30364247 | 0.78 | BTK (0.39) | BTKEPHX1HRH3MAPK1HPGD | |
| SCHEMBL25453169 | 0.78 | BTK (0.39) | BTKEPHX1HRH3MAPK1HPGD | |
| SCHEMBL2502211 | 0.78 | BTK (0.39) | BTKEPHX1HRH3MAPK1HPGD | |
| SCHEMBL13918262 | 0.78 | SLC6A2 (0.42) | GABRR1GABRR2EPHX1CHRM2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034440-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034440-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | BHMT, CBS, BHMT2 | GABRR1 3176/4885GABRR2 3662/4885PEPD 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.